Skip to Content

Rapivab Approval History

  • FDA approved: Yes (First approved December 19th, 2014)
  • Brand name: Rapivab
  • Generic name: peramivir
  • Dosage form: Injection
  • Company: BioCryst Pharmaceuticals, Inc.
  • Treatment for: Influenza

Rapivab (peramivir) is an influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza.

Development History and FDA Approval Process for Rapivab

Sep 21, 2017Approval BioCryst's Rapivab (peramivir injection) Receives FDA Approval for a Pediatric Indication
Dec 22, 2014Approval FDA Approves Rapivab (peramivir) to Treat Influenza Infection
Sep 10, 2014BioCryst Announces Rapivab (peramivir injection) Trial Results for the Treatment of Influenza
Feb 25, 2014BioCryst Announces Peramivir NDA Acceptance by the FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.